Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-06-21
DOI
10.3389/fonc.2019.00510
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
- (2018) G N Hortobagyi et al. ANNALS OF ONCOLOGY
- Targeting FGFR pathway in breast cancer
- (2018) J. Perez-Garcia et al. BREAST
- Targeted therapy for premenopausal women with HR+, HER2- advanced breast cancer: focus on special considerations and latest advances
- (2018) Aditya Bardia et al. CLINICAL CANCER RESEARCH
- Implications of ESR1 Mutations in Hormone Receptor-Positive Breast Cancer
- (2018) Tomás Reinert et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3
- (2018) Dennis J. Slamon et al. JOURNAL OF CLINICAL ONCOLOGY
- Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
- (2018) Debu Tripathy et al. LANCET ONCOLOGY
- Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2018) Angelo Di Leo et al. LANCET ONCOLOGY
- Endocrine Therapy in Premenopausal Hormone Receptor Positive/Human Epidermal Growth Receptor 2 Negative Metastatic Breast Cancer: Between Guidelines and Literature
- (2018) Richard Tancredi et al. ONCOLOGIST
- Evaluation of drug mechanism and efficacy of a novel anti-angiogenic agent, TTAC-0001, using multi-modality bioimaging in a mouse breast cancer orthotopic model
- (2018) Jinil Kim et al. PLoS One
- Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2– advanced breast cancer
- (2018) Silvia Paola Corona et al. Drug Design Development and Therapy
- The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade
- (2018) David A. Schaer et al. Cell Reports
- Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study)
- (2018) Ji-Yeon Kim et al. EUROPEAN JOURNAL OF CANCER
- LBA3_PRAlpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial
- (2018) F André et al. ANNALS OF ONCOLOGY
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
- (2017) George W. Sledge et al. JOURNAL OF CLINICAL ONCOLOGY
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
- (2017) Matthew P. Goetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) José Baselga et al. LANCET ONCOLOGY
- The use of high-dose estrogens for the treatment of breast cancer
- (2017) Herjan J.T. Coelingh Bennink et al. MATURITAS
- The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer
- (2017) Rinath Jeselsohn et al. Current Oncology Reports
- Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer
- (2017) Tomas Reinert et al. Frontiers in Oncology
- Results of ENCORE 301, a randomized, phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive (ER+) breast cancer progressing on a nonsteroidal aromatase inhibitor (AI).
- (2017) D. A. Yardley et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety of everolimus plus exemestane in patients with hormone-receptor–positive, HER2–negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)
- (2016) G. Jerusalem et al. ANNALS OF ONCOLOGY
- Systemic Therapy of Advanced/Metastatic Breast Cancer - Current Evidence and Future Concepts
- (2016) Cornelia Liedtke et al. Breast Care
- Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer
- (2016) Romualdo Barroso-Sousa et al. Breast Care
- Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
- (2016) Hope S. Rugo et al. JOURNAL OF CLINICAL ONCOLOGY
- Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
- (2016) John F R Robertson et al. LANCET
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
- (2016) Massimo Cristofanilli et al. LANCET ONCOLOGY
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- ActivatingESR1Mutations Differentially Affect the Efficacy of ER Antagonists
- (2016) Weiyi Toy et al. Cancer Discovery
- Sunitinib as salvage treatment including potent anti-tumor activity in carcinomatous ulcers for patients with multidrug-resistant metastatic breast cancer
- (2016) Bing Sun et al. Oncotarget
- Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation
- (2016) Sean W Fanning et al. eLife
- Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer
- (2015) S. E. Wardell et al. CLINICAL CANCER RESEARCH
- Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients
- (2015) P. Wang et al. CLINICAL CANCER RESEARCH
- Selective estrogen receptor modulators in clinical practice: a safety overview
- (2015) Amanda J Ellis et al. Expert Opinion On Drug Safety
- Buparlisib in breast cancer
- (2015) Bhawna Sirohi et al. Future Oncology
- Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study
- (2015) Miguel Martín et al. JOURNAL OF CLINICAL ONCOLOGY
- Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens
- (2015) Takashi Takeshita et al. Translational Research
- Phase 3, open-label, randomized study comparing 3-monthly with monthly goserelin in pre-menopausal women with estrogen receptor-positive advanced breast cancer
- (2015) Shinzaburo Noguchi et al. Breast Cancer
- Molecular mechanisms of tamoxifen-associated endometrial cancer (Review)
- (2015) RONG HU et al. Oncology Letters
- The Fibroblast Growth Factor signaling pathway
- (2015) David M. Ornitz et al. Wiley Interdisciplinary Reviews-Developmental Biology
- Everolimus Plus Exemestane for the Treatment of Advanced Breast Cancer: A Review of Subanalyses from BOLERO-2
- (2015) Gabriel N. Hortobagyi NEOPLASIA
- Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial†
- (2014) J. Bines et al. ANNALS OF ONCOLOGY
- Breast cancer in young women: have the prognostic implications of breast cancer subtypes changed over time?
- (2014) Wilson Sheridan et al. BREAST CANCER RESEARCH AND TREATMENT
- US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
- (2014) Nadia Howlader et al. JNCI-Journal of the National Cancer Institute
- Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
- (2013) Denise A. Yardley et al. ADVANCES IN THERAPY
- Phase III Trial of Sunitinib in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Patients With Pretreated Metastatic Breast Cancer
- (2013) John P. Crown et al. JOURNAL OF CLINICAL ONCOLOGY
- Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial
- (2013) A. D. Leo et al. JNCI-Journal of the National Cancer Institute
- Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial
- (2013) Stephen RD Johnston et al. LANCET ONCOLOGY
- Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer
- (2012) Rupert Bartsch et al. EUROPEAN JOURNAL OF CANCER
- A historical perspective of aromatase inhibitors for ovulation induction
- (2012) Robert F. Casper et al. FERTILITY AND STERILITY
- The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer
- (2012) Julia A Beaver et al. Future Oncology
- The mTOR Signalling Pathway in Human Cancer
- (2012) Helena Pópulo et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Hazard of Breast Cancer-Specific Mortality among Women with Estrogen Receptor-Positive Breast Cancer after Five Years from Diagnosis: Implication for Extended Endocrine Therapy
- (2012) Ke-Da Yu et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone As First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer
- (2012) Jonas Bergh et al. JOURNAL OF CLINICAL ONCOLOGY
- First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study
- (2012) Jonas Bergh et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study
- (2012) Thomas Bachelot et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
- (2012) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- Whole-genome analysis informs breast cancer response to aromatase inhibition
- (2012) Matthew J. Ellis et al. NATURE
- Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer
- (2012) Rita S. Mehta et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of toremifene versus tamoxifen on breast cancer patients: a meta-analysis
- (2012) Feng Chi et al. Breast Cancer
- Clinical and biomarker predictors of side effects from tamoxifen
- (2011) Wendy Lorizio et al. BREAST CANCER RESEARCH AND TREATMENT
- Abstract S1-6: TAMRAD: A GINECO Randomized Phase II Trial of Everolimus in Combination with Tamoxifen Versus Tamoxifen Alone in Patients (pts) with Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer (MBC) with Prior Exposure to Aromatase Inhibitors (AI).
- (2011) T Bachelot et al. CANCER RESEARCH
- Endocrine Therapy of Breast Cancer
- (2011) F. Lumachi et al. CURRENT MEDICINAL CHEMISTRY
- Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: Results from AVADO
- (2011) Xavier Pivot et al. EUROPEAN JOURNAL OF CANCER
- Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy
- (2011) Seth A. Wander et al. JOURNAL OF CLINICAL INVESTIGATION
- Intersection of FOXO- and RUNX1-mediated gene expression programs in single breast epithelial cells during morphogenesis and tumor progression
- (2011) L. Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Novel Agents and Future Directions for Refractory Breast Cancer
- (2011) Harold J. Burstein SEMINARS IN ONCOLOGY
- Proteasome inhibitors in cancer therapy
- (2011) Lisa J. Crawford et al. Journal of Cell Communication and Signaling
- Functional Genetic Polymorphisms in the Aromatase Gene CYP19 Vary the Response of Breast Cancer Patients to Neoadjuvant Therapy with Aromatase Inhibitors
- (2010) L. Wang et al. CANCER RESEARCH
- Low-Molecular-Weight Cyclin E Can Bypass Letrozole-Induced G1 Arrest in Human Breast Cancer Cells and Tumors
- (2010) S. Akli et al. CLINICAL CANCER RESEARCH
- Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer
- (2010) Angelo Di Leo et al. JOURNAL OF CLINICAL ONCOLOGY
- Breast Cancer Subtypes and the Risk of Local and Regional Relapse
- (2010) K. David Voduc et al. JOURNAL OF CLINICAL ONCOLOGY
- Delineating Genetic Alterations for Tumor Progression in the MCF10A Series of Breast Cancer Cell Lines
- (2010) Mitsutaka Kadota et al. PLoS One
- Targeting a Common Collaborator in Cancer Development
- (2010) A. P. Myers et al. Science Translational Medicine
- Ovarian ablation by radiation therapy: Is it still an option for the ablation of ovarian function in endocrine responsive premenopausal breast cancer patients?
- (2009) Nuran S. Bese et al. BREAST
- The Role of Fibroblast Growth Factors in Tumor Growth
- (2009) M. Korc et al. CURRENT CANCER DRUG TARGETS
- Therapeutic options for metastatic breast cancer
- (2009) Patrick G Morris et al. EXPERT OPINION ON PHARMACOTHERAPY
- mTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptor α serine 167 phosphorylation
- (2009) Rachel L. Yamnik et al. FEBS LETTERS
- Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer
- (2009) Robert Gray et al. JOURNAL OF CLINICAL ONCOLOGY
- S6 Kinase 1 Regulates Estrogen Receptor α in Control of Breast Cancer Cell Proliferation
- (2008) Rachel L. Yamnik et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT
- (2008) Stephen Chia et al. JOURNAL OF CLINICAL ONCOLOGY
- Phosphorylated ERα, HIF-1α, and MAPK Signaling As Predictors of Primary Endocrine Treatment Response and Resistance in Patients With Breast Cancer
- (2008) Daniele Generali et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now